- RecruitingPHASE3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukemia (AML) in people who are newly diagnosed. It's comparing a new drug, bleximenib, with existing treatments (Venetoclax and Azacitidine) and a dummy drug (placebo) to see how well they work.
For: Leukemia, Myeloid, AcuteUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
Study to Evaluate the Safety and Tolerability of EP0042
This study is looking at a new treatment called EP0042 for advanced blood cancers like acute myeloid leukaemia (AML). It aims to find a safe and effective dose of EP0042, sometimes combined with other medicines, for patients whose cancer treatments haven't worked or have stopped working.
For: Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic SyndromesAustralia · Netherlands · United Kingdom - RecruitingPHASE3
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
This study is testing a new drug, ziftomenib, for a type of blood cancer called AML. It combines ziftomenib with standard treatments for patients who haven't had treatment before, aiming to see if it works better than usual care alone.
For: Acute Myeloid Leukemia (AML)United States · Czechia · France - Active not recruitingPHASE1
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
This study is testing a new drug called Bleximenib alongside standard treatments for acute myeloid leukaemia (AML). It aims to find the safest and most effective dose of Bleximenib when given with other AML medicines, and to understand its side effects.
For: Leukemia, Myeloid, AcuteUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
This study is testing a new drug, Enzomenib, for people with certain types of leukaemia or blood cancers like MDS and Multiple Myeloma. It will look at its safety and how well it works, both alone and with other common treatments.
For: Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Acute · Multiple MyelomaUnited States · Belgium · Canada - RecruitingPHASE2
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
This study looks at combining a new drug, Gilteritinib, with standard treatments (Venetoclax and Azacitidine) for acute myeloid leukaemia (AML) in patients who have a specific gene change (FLT3 mutation) and can't have strong chemotherapy. It aims to find the safest and most effective dose.
For: AML - Acute Myeloid LeukemiaGermany